In this regard, the frequency of TP53 abnormalities observed in early stages, such as chronic cholecystitis, can be subgrouped into 35% of LOH, 25% of mutations, and 11% of gene inactivation; meanwhile, in invasive GBC the frequency is 81%, 67 %, and 52%, respectively. The gene discussed is TP53; the disease is Cholecystitis.